Background

•
Cytokine modulators are high-cost biologics used primarily in paediatric rheumatology to treat patients with juvenile idiopathic arthritis (JIA).
• Funding mechanisms are unreliable and inconsistent hence appropriate dose rounding is a key cost-saving measure.
• Lack of evidence-based guidance for dose rounding in paediatrics. 
Aims and objectives
Method
• Retrospective data collection of electronic prescriptions for all cytokine modulators prescribed for rheumatology inpatients from January 2011 to December 2014.
•
Prescriptions analysed using five step process to determine if doses could have been rounded to nearest whole dose unit.
Cost of waste resulting from failure to dose round also calculated.
Results and discussion
• 1,979 eligible prescriptions identified. 44% (879/1979) excluded as did not require dose rounding or unable to be dose rounded within tolerance limits (figure 1).
Figure 1: Percentage of prescriptions appropriately dose rounded to the nearest vial, pen or syringe (green = contributes to audit standard) (red = does not contribute to audit standard)
• 3.5% (39/1100) of prescriptions already rounded by the prescriber outside of the 5-10% proposed dose rounding tolerance. This suggests that there may be some scope to increase the tolerance limit to allow for more dose rounding to be undertaken. • Only 35% (380/1100) of prescriptions able to be appropriately dose rounded to the nearest whole vial, pen or syringe were done so; hence audit standard not met by a substantial margin. This is perhaps expected as there are no trust dose rounding guidelines. Prescriptions for tocilizumab (562/750) and infliximab (136/204) accounted for 97% (698/720) not appropriately dose rounded. Tocilizumab and infliximab are used frequently as first line inpatient treatments for systemic-onset JIA (SoJIA) and other forms of JIA respectively. Hence, given their frequent use it is key they are prescribed and supplied in the most cost-effective way.
• £32,000/year of drug wasted. 35% (£11,300/£32,000) is avoidable by appropriate dose rounding (figure 2), 96% (£10,800/£11,300) of avoidable wastage related to infliximab and tocilizumab. 
